<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>Pengobatan Malaria</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Emiliana</mods:namePart><mods:namePart type="family">Tjitra</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Treatment is the aimed to cure the patients of their disease, rather than reducing parasite reservoirs. Chloroquine is the standard antimalarial drug for chemoprophylaxis, clinical malaria treatment and radical treatment. While sulfadoxine-pyrimethamine and quinine are resistant areas. Parenteral quinine is a life-saving antimalarial drug for severe and complicated malaria. Primaquine is a supplement of standard antimalarial drug for radical treatment.      Supportive therapy is given depending on clinical manifestations of organ dysfunction. Several new antimalarial drugs are mefloquine, halofantrine and artemisinine derivates have been studied.</mods:abstract><mods:classification authority="lcc">WC 680-950 Tropical and Parasitic Diseases</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8601">1996</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Ikatan Dokter Indonesia</mods:publisher></mods:originInfo><mods:genre>Article</mods:genre></mods:mods>